BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 31543336)

  • 1. Outcome after pancreatectomy for neuroendocrine neoplams according to the WHO 2017 grading system: A retrospective multicentric analysis of 138 consecutive patients.
    Souche R; Coignac A; Dupuy M; Bertrand M; Raingeart I; Guiu B; Herrero A; Panaro F; Obled S; Portales F; Riviere B; Ramos J; Borie F; Quenet F; Colombo PE; Prudhomme M; Assenat E; Fabre JM; ;
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):286-294. PubMed ID: 31543336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
    Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the World Health Organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors.
    Yang M; Tian BL; Zhang Y; Su AP; Yue PJ; Xu S; Wang L
    Pancreas; 2014 Oct; 43(7):1003-8. PubMed ID: 24945681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of surgery for pancreatic neuroendocrine neoplasms.
    Fischer L; Bergmann F; Schimmack S; Hinz U; Prieß S; Müller-Stich BP; Werner J; Hackert T; Büchler MW
    Br J Surg; 2014 Oct; 101(11):1405-12. PubMed ID: 25132004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience.
    Ito H; Abramson M; Ito K; Swanson E; Cho N; Ruan DT; Swanson RS; Whang EE
    J Gastrointest Surg; 2010 May; 14(5):891-8. PubMed ID: 20224984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival.
    Birnbaum DJ; Turrini O; Ewald J; Barbier L; Autret A; Hardwigsen J; Brunet C; Moutardier V; Le Treut YP; Delpero JR
    Eur J Surg Oncol; 2014 Nov; 40(11):1564-71. PubMed ID: 25086992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
    Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
    Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
    Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis.
    Cloyd JM; Kopecky KE; Norton JA; Kunz PL; Fisher GA; Visser BC; Dua MM; Park WG; Poultsides GA
    Surgery; 2016 Sep; 160(3):708-13. PubMed ID: 27216830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidisciplinary treatment strategy for advanced pancreatic neuroendocrine tumors- a single center experience.
    Tsuchikawa T; Hirano S; Tanaka E; Kato K; Matsumoto J; Sichinohe T
    Hepatogastroenterology; 2012; 59(120):2623-6. PubMed ID: 22497945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours.
    Ricci C; Casadei R; Taffurelli G; Campana D; Ambrosini V; Pagano N; Santini D; De Giorgio R; Ingaldi C; Tomassetti P; Zani E; Minni F
    Pancreatology; 2016; 16(3):403-10. PubMed ID: 26924664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification.
    Brunner SM; Weber F; Werner JM; Agha A; Farkas SA; Schlitt HJ; Hornung M
    BMC Surg; 2015 Apr; 15():49. PubMed ID: 25928025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value and Clinical Predictors of Lymph Node Metastases in Pancreatic Neuroendocrine Tumors.
    Zhang Z; Liu M; Ji S; Luo G; Xu W; Liu W; Hu Q; Sun Q; Ye Z; Qin Y; Fan G; Yu X; Xu X
    Pancreas; 2020 Mar; 49(3):381-386. PubMed ID: 32132507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study.
    Sallinen VJ; Le Large TYS; Tieftrunk E; Galeev S; Kovalenko Z; Haugvik SP; Antila A; Franklin O; Martinez-Moneo E; Robinson SM; Panzuto F; Regenet N; Muffatti F; Partelli S; Wiese D; Ruszniewski P; Dousset B; Edwin B; Bartsch DK; Sauvanet A; Falconi M; Ceyhan GO; Gaujoux S;
    HPB (Oxford); 2018 Mar; 20(3):251-259. PubMed ID: 28988702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group.
    Primavesi F; Klieser E; Cardini B; Marsoner K; Fröschl U; Thalhammer S; Fischer I; Hauer A; Urbas R; Kiesslich T; Neureiter D; Zitt M; Klug R; Wundsam H; Sellner F; Karner J; Függer R; Cakar-Beck F; Kornprat P; Öfner D; Stättner S;
    Eur J Surg Oncol; 2019 Feb; 45(2):198-206. PubMed ID: 30262324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
    Merola E; Rinke A; Partelli S; Gress TM; Andreasi V; Kollár A; Perren A; Christ E; Panzuto F; Pascher A; Jann H; Arsenic R; Cremer B; Kaemmerer D; Kump P; Lipp RW; Agaimy A; Wiedenmann B; Falconi M; Pavel ME
    Ann Surg Oncol; 2020 May; 27(5):1348-1355. PubMed ID: 31720931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter?
    Sallinen V; Haglund C; Seppänen H
    Surgery; 2015 Dec; 158(6):1556-63. PubMed ID: 26070847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of Lymph Node Metastasis in Resectable Well-differentiated Pancreatic Neuroendocrine Tumor.
    Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
    Pancreas; 2019 Aug; 48(7):943-947. PubMed ID: 31268980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.